Franklin, TN, United States of America

Roy A Jensen

This inventor holds 9 USPTO granted patents. Top assignees: Vanderbilt University, The United States of America as Represented by the Department of Health, University of Washington. Active years: 1993-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roy A Jensen. Retrieved from https://idiyas.com/inventor/roy-a-jensen-h7880rtl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 78(Granted Patents)


Location History:

  • Melrose, FL (US) (1993)
  • Franklin, TN (US) (1995 - 2002)

Company Filing History:


Years Active: 1993-2002

Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Roy A. Jensen in Cancer Research

Introduction

Roy A. Jensen, based in Franklin, TN, has made significant strides in the field of cancer research through his innovative inventions. With a total of 9 patents to his name, Jensen's work focuses on methods for the detection and treatment of prevalent cancers such as breast and prostate cancer. His research has not only advanced the understanding of these diseases but has also paved the way for novel therapeutic approaches.

Latest Patents

Jensen's latest patents include a groundbreaking method for the detection and treatment of breast cancer. This invention centers on identifying differentially expressed genes in early, pre-invasive breast cancer tissue. By utilizing microscopically-directed tissue sampling techniques along with differential display or screening of cDNA libraries, Jensen demonstrates how genetic markers can indicate the presence of pre-invasive cancerous tissues. Moreover, he confirms the differential expression of genes through RT-PCR, nuclease protection assays, and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA.

Additionally, Jensen’s therapeutic methods for prostate cancer encompass gene therapy utilizing the BRCA family of genes, including BRCA1 and BRCA2, which play crucial roles in inhibiting the growth and tumorigenesis of prostate cancer cells. These methodologies represent significant advancements in cancer therapy and provide new avenues for treatment.

Career Highlights

Throughout his career, Roy A. Jensen has held positions at prestigious institutions, including Vanderbilt University and the University of Washington. His tenure at these institutions has contributed to the depth of his research and the breadth of his innovative approaches in oncology.

Collaborations

Collaboration has been a key aspect of Jensen's work, as he has partnered with notable individuals such as Jeffrey T. Holt and Cheryl L. Robinson-Benion. These collaborations have enriched his research and have facilitated the development of his patented methodologies.

Conclusion

Roy A. Jensen represents a pioneering force in the field of cancer research. His patents portray a commitment to advancing medical science through innovative solutions for cancer detection and treatment. With a career marked by collaboration and significant contributions, Jensen continues to inspire future generations in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…